What is Bexion Pharmaceuticals?
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to pioneering novel biologic therapies for challenging solid tumors and the debilitating side effect of chemotherapy-induced peripheral neuropathy (CIPN). Their flagship therapeutic candidate, BXQ-350, is currently being investigated for its efficacy in treating metastatic colorectal cancer, with a dual objective of combating the malignancy while simultaneously mitigating the neuropathic pain often associated with standard cancer treatments. Promising Phase 1 clinical trial data has been presented, validating the company's therapeutic approach. Bexion is strategically focused on broadening its product portfolio to encompass a wider array of oncological indications and to address the pervasive issue of neuropathic pain across various patient populations. A seasoned, multidisciplinary team guides Bexion's mission to develop patient-centric therapeutics designed to markedly enhance the quality of life for individuals battling cancer.
How much funding has Bexion Pharmaceuticals raised?
Bexion Pharmaceuticals has raised a total of $463K across 2 funding rounds:
Debt
$150K
Debt
$313K
Debt (2020): $150K with participation from PPP
Debt (2021): $313K led by PPP
Key Investors in Bexion Pharmaceuticals
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Bexion Pharmaceuticals?
With substantial backing and a clear focus on late-stage development, Bexion Pharmaceuticals is poised for significant advancements. The recent strategic investment will likely accelerate the progression of BXQ-350 through further clinical trials, potentially paving the way for regulatory submission and market entry. The company's commitment to expanding its therapeutic pipeline suggests ongoing research and development efforts aimed at addressing unmet needs in oncology and pain management. Future funding rounds may be anticipated to support commercialization activities and the broader expansion of their innovative biologic therapies.
See full Bexion Pharmaceuticals company page
